Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta

Microsoft Launches New Tool Kit;
Chats About Vista
The big news out of AC is the release of Microsoft’s Office for Business Applications (OBA) for the life sciences industry. This set of tools allows software developers to build applications that seamlessly connect back-end enterprise systems with MS Office program.
Paul Mattes, Microsoft’s Managing Director of Health and Life Sciences, gave us an example in layman’s terms. Picture an executive typing an article in MS Word. He stumbles on a compound name and isn’t sure of the correct spelling. MS Word will underline the compound, much like it would for a misspelled word, and the author has the option of either querying the word against the company’s compound database in its enterprise system or even importing the molecular structure of the compound directly into MS Word. The best part is that you never have to switch programs or computers to get the information.
Another application in development using the OBA tool kit would allow a person working on an FDA submissions document to make changes in MS Word and then press a single key to send it to the next person. The most useful aspect? A digital signature is created for every person that touches the document. Sadly, Mattes said that there is no program in development that would allow pharma to click a button and send the document directly to the FDA.
The company plans to have some of the programs developed through OBA for show at the upcoming DIA convention in June.
OS Adoption
The big question on my mind, however, was how Microsoft’s embattled Vista operating system is being accepted by pharma, an industry that is slow to adopt new technology when it doesn’t have a ton of negative press attached to it.
“Everyone is interested in Vista and we are actively engaging in deployment,” Mattes said. “There is a business imperative right now to drive collaborative efficiencies right now. We are seeing more and more customers right now that see Vista as an enabler right now. Vista is seeing a higher adoption rate than XP when it first launched. However. adoption started in areas that aren’t subject to regulatory restraints.” Translation: Not pharma.